UK markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
69.00-0.56 (-0.81%)
At close: 4:00PM EST

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400

Full-time employees232

Key executives

NameTitlePayExercisedYear born
Dr. Christopher R. AnzaloneCEO, Pres & Director1.61M3.07M1969
Mr. Kenneth A. MyszkowskiChief Financial Officer690.3k4.25M1966
Dr. Bruce D. GivenAdvisor486.31k5.93M1954
Dr. Javier San MartinChief Medical Officer673.57kN/A1965
Mr. James HassardChief Commercial Officer488.3kN/A1967
Dr. Mark M. DavisFounder and Founder & Director of Insert Therapeutics Inc & CalandoN/AN/AN/A
Ms. Jane DavidsonHead of HR & Admin., VP and Corp. Sec.N/AN/AN/A
Dr. Vincent AnzaloneVP of Investor RelationsN/AN/AN/A
Mr. Patrick O'BrienChief Compliance Officer, Gen. Counsel & Corp. Sec.N/AN/A1964
Mr. Howard LovyDirector of CommunicationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Corporate governance

Arrowhead Pharmaceuticals, Inc.’s ISS governance QualityScore as of 3 December 2020 is 4. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.